证券代码：688068 证券简称：热景生物 公告编号：2024-064 北京热景生物技术股份有限公司 股东询价转让定价情况提示性公告 周锌保证向北京热景生物技术股份有限公司（以下简称"公司"）提供的信 息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性 和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据2024年9月9日询价申购情况，初步确定的本次询价转让价格为21.46 元/股。 受让方通过询价转让受让的股份，在受让后6个月内不得转让。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 21.46 元/股。 （二）参与本次询价转让报价的机构投资者家数为 6 家，涵盖了基金管理公 司、私募基金管理人等专业机构投资者。参与本次询价转让报价的机构投资者合 计有效认购股份数量为 1,900,000 股，对应的有效认购倍数为 1.90 倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 4 家机构 投资者，拟受让股份总数为 1,000,000 股。 二、风险提示 （一）本次询价转让受让方及受让 ...

中国国际金融股份有限公司 关于北京热景生物技术股份有限公司 股东向特定机构投资者询价转让股份 （一）核查过程 根据相关法规要求，中金公司已于 2024 年 9 月 5 日完成出让方相关资格的 核查工作，包括核查出让方提供的身份证明文件、出让方股权权属证明文件、 《承诺及声明函》等文件，并通过公开信息渠道检索等手段对出让方资格进行 核查，同时收集了相关核查底稿。 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受北京热景生物技 术股份有限公司（以下简称"热景生物"）周锌（以下亦称"出让方"）委托， 组织实施本次热景生物股东向特定机构投资者询价转让（以下简称"本次询价 转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科 创板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售》 （以下简称"《询价转让和配售指引》"）等相关规定，中金公司对参与本次 询价出让方的相关资格进行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让概述 2024 年 8 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-063 北京热景生物技术股份有限公司 股东询价转让计划书 周锌（以下简称"出让方"）保证向北京热景生物技术股份有限公司（以 下简称"热景生物"或"公司"）提供的信息内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 重要内容提示： 拟参与热景生物首发前股东询价转让（以下简称"本次询价转让"）的 股东为周锌； 出让方拟转让股份的总数为 1,000,000 股，占热景生物股本的比例为 1.08%； 本次询价转让为非公开转让，不会通过集中竞价交易方式进行；受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实 施本次询价转让。截至 2024 年 8 月 30 日，出让方所持首发前股份的数量、占 公司总股本比例情况如下： 出让方承诺有 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 20% increase compared to the same period last year[1]. - The company has provided a revenue guidance of RMB 1.2 billion for the full year 2024, which reflects an expected growth of 25% year-over-year[1]. - The company's revenue for the first half of 2024 was ¥248,810,028.12, a decrease of 18.96% compared to ¥307,007,061.27 in the same period last year[12]. - The net profit attributable to shareholders was -¥43,467,813.74, representing a decline of 151.28% from ¥84,768,666.87 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥76,826,781.14, a decrease of 245.72% compared to ¥52,722,824.78 last year[12]. - The company's cash flow from operating activities was -¥3,839,453.46, a significant improvement from -¥199,519,286.00 in the previous year, indicating a 98.08% reduction in cash outflow[12]. - The total assets at the end of the reporting period were ¥3,372,834,166.06, down 5.56% from ¥3,571,560,503.77 at the end of the previous year[12]. - The net assets attributable to shareholders decreased by 4.80% to ¥3,205,963,662.46 from ¥3,367,489,040.66 at the end of the previous year[12]. - The basic earnings per share for the reporting period was -¥0.47, a decrease of 149.55% from ¥0.95 in the same period last year[13]. - The company's revenue from non-COVID-related business increased by 21.53% to ¥239,506,400, while COVID-related revenue dropped by 91.54%[13]. Research and Development - The R&D expenditure for new products and technologies increased by 30%, amounting to RMB 150 million in the first half of 2024[1]. - R&D expenses accounted for 19.95% of operating revenue, a decrease of 2.24 percentage points compared to the same period last year; R&D expenses decreased by CNY 18.47 million, a decline of 27.12%[14]. - The company has developed a comprehensive liver health management platform, covering early diagnosis and screening for liver diseases, including liver cancer[18]. - The company’s subsidiary, ShunJing Pharmaceutical, is developing innovative drugs with 10 therapeutic monoclonal antibody projects in progress, 5 of which have completed molecular discovery[20]. - The company is actively expanding its strategic layout in the field of biopharmaceuticals through incubation and equity participation in innovative drug companies[20]. - The R&D investment strategy focuses on innovative diagnostic technologies and expanding the core technology platforms in the field of in vitro diagnostics[18]. - The company has achieved significant technological breakthroughs in the diagnosis of high-incidence gastrointestinal tumors such as liver and gastric cancers, as well as Alzheimer's disease, during the reporting period[52]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - A strategic acquisition of a local biotech firm was completed, enhancing the company's product portfolio and expected to contribute an additional RMB 200 million in revenue[1]. - The company is focusing on developing innovative products in the fields of liver disease and pancreatic cancer diagnostics, leveraging its proprietary technologies to enhance market competitiveness[26]. - The company is actively expanding its strategic layout, focusing on three major health projects: "National Liver Health Project," "National Brain Health Project," and "National Cancer Early Detection and Screening Project," leveraging its proprietary sugar capture technology[70]. Regulatory and Compliance - The board of directors confirmed that there are no non-operational fund usages by controlling shareholders or related parties[1]. - The company has received clinical trial approvals from both the FDA and CDE for its SGC001 drug candidate[20]. - The company has received regulatory approval for its hair drug testing kit, which offers unique advantages such as longer detection windows and comprehensive drug use history, positioning it as a key growth area[27]. - The company has made long-term commitments to avoid competition with its controlling shareholders and related parties, ensuring no direct or indirect engagement in similar businesses[123]. Risks and Challenges - The company has identified potential risks but stated that there are no substantial adverse impacts expected during the reporting period[1]. - The company faces risks in new product development due to the fast-paced nature of the in vitro diagnostics industry, which may lead to potential R&D failures[89]. - The company is at risk of losing core technical personnel, which could delay ongoing projects and impact future product development[89]. - The company must navigate regulatory changes in product registration, which could adversely affect its business continuity if not managed properly[90]. Innovation and Technology - The company has established multiple advanced technology platforms, including phage display technology for antibody production, with domestic leadership and international advancement[34]. - The company has developed unique public safety testing products, including drug abuse detection kits, utilizing up-conversion luminescence technology[55]. - The company has launched the first III class drug hair testing reagents in China, marking a significant advancement in drug detection technology[66]. - The company has developed a rapid detection standard for mycotoxins in feed, collaborating with several agricultural institutions[31]. Corporate Governance - The company has maintained good integrity status during the reporting period, with no unfulfilled court judgments or significant overdue debts[130]. - The company has not provided any guarantees that violate regulations during the reporting period[129]. - The company has not disclosed any new matters related to major related transactions during the reporting period[131]. Social Responsibility - The company actively supports poverty alleviation and rural revitalization efforts in Lin Tun Village, Anhui Province, through a cherry greenhouse project[122]. - The company has implemented measures to manage waste, including wastewater treatment and solid waste disposal, in compliance with national standards[120].

证券代码：688068 证券简称：热景生物 公告编号：2024-062 （二）报告期内，募集资金使用和结余情况 2024 年 1-6 月，公司募集资金使用情况为：（1）上述募集资金到账前，截至 2019 年 9 月 24 日止，公司利用自筹资金对募集资金项目累计已投入 531.40 万 元，募集资金到账后，公司以募集资金置换预先已投入募集资金投资项目的自筹 资金 531.40 万元；（2）2024 年 1-6 月直接投入募集资金项目 160.45 万元，累计 使用募集资金 34,732.77 万元，扣除累计已使用募集资金后，募集资金余额为 5,174.32 万元，募集资金专用账户利息收入 1,746.43 万元，募集资金专用账户手 续费为 0.14 万元，使用超募资金永久补充流动资金 6,306.36 万元，募集资金专 1 北京热景生物技术股份有限公司 2024 年半年度 募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额及资金到账时间 依据中国 ...

| 序号 | 产品英文名称 | 产品中文名称 | 注册证号 （备案号） | 分类 | 发证日期 | 有效期至 | 发证 国家 | | --- | --- | --- | --- | --- | --- | --- | --- | | | Procalcitonin test | 降钙素原测定试剂 | KEMENKES RI | | | | | | 1 | (Chemiluminescence | 盒（磁微粒化学发光 | AKL | Class B | 2024/7/9 | 2028/11/28 | 印尼 | | | Immunoassay) | 免疫分析法） | 20101421347 | | | | | | | Thyroxine test | 总甲状腺素测定试 | KEMENKES RI | | | | | | 2 | (Chemiluminescence | 剂盒（磁微粒化学发 | AKL | Class B | 2024/7/5 | 2028/11/28 | 印尼 | | | Immunoassay) | 光免疫分析法） | 20101421325 | | | | | | | Glycosylated ...

SGC001 是一款由舜景医药孙志伟教授研发团队联合首都医科大学北 京市心肺血管疾病研究所杜杰教授团队共同开发研制的急救用单克隆抗 体药物，适用于急性心肌梗死（Acute Myocardial Infarction, AMI）(首先开 展的适应症为"前壁 ST 段抬高型心肌梗死")患者的急救治疗。此前，针 对 AMI 疾病，暂无相关抗体药物进入临床研究阶段及审批上市。截至本公 告日，SGC001 临床试验申请（IND）已先后获得美国食品药品监督管理局（FDA） 及国家药品监督管理局（NMPA）批准许可。 二、疾病特点及诊疗现状 证券代码：688068 证券简称：热景生物 公告编号：2024-058 北京热景生物技术股份有限公司 关于参股公司 SGC001 创新药研发进展的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，北京热景生物技术股份有限公司（以下简称"公司"或"热景生物"） 参股公司北京舜景生物医药技术有限公司（以下简称"舜景医药"）收到国家药 品监督管理局（NMPA）核准签发的《药物临床试验批 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-057 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）近日获得国内医疗器械 注册证 2 项。相关信息如下： 一、获得资质的具体情况 （一） 获得国内医疗器械注册证情况 北京热景生物技术股份有限公司 关于公司近日获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 特此公告。 | 序号 | 产品名称 | 注册证号 | 类别 | 发证日期 | 有效期至 | 发证机构 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 氯胺酮头发检测试剂盒 | 国械注准 | III | 2024.07.23 | 2029.07.22 | 国家药品监督管 | | | （上转发光法） | 20243401306 | | | | 理局 | | 2 | 甲基安非他明头发检测试 | 国械注准 | III | 2024.07.23 | 2029.07.22 | 国家药品监督管 | | | 剂盒（上转发光法） | 202 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-055 北京热景生物技术股份有限公司 关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）近期获得国内医疗器械 注册证/备案证 10 项，获得境外资质认证 13 项。相关信息如下： 一、获得资质的具体情况 （一） 获得国内医疗器械注册证/备案证情况 | （二）获得境外认证情况 | | --- | | 序号 | 产品英文名称 | 产品中文名称 | 注册证号 | 分类 | 发证日期 | 有效期至 | 发证 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | （备案号） | | | | 国家 | | | Glycosylated Hemoglobin | 糖化血红蛋白测定 | IMP/IVD/2024/ | | | | | | 1 | Chemiluminescence | 试剂盒(磁微粒化学 | 0000 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-054 根据《北京热景生物技术股份有限公司 2024 年员工持股计划》的相关规定， 本次员工持股计划的存续期为 48 个月，自公司公告最后一笔标的股票过户至本 次员工持股计划名下之日起计算。本次员工持股计划所获标的股票分三期解锁， 解锁时点分别为自公司公告最后一笔标的股票过户至本次员工持股计划名下之 日起满 12 个月、24 个月、36 个月，每期解锁标的股票比例分别为 40%、30%、 30%，各期具体解锁比例和数量根据公司业绩考核的完成情况和持有人个人年度 绩效考核结果综合计算确定。 公司将持续关注本次员工持股计划的实施进展情况，并按照相关规定及时履 行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 关于 2024 年员工持股计划完成非交易过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）分别于 2024 年 4 月 26 日召开第三届董事会第二十次会议和第三届监事会第十七次会议、2024 ...